ReviewJournal of neuroendocrinology2025
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.
Review in Journal of neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.International journal of cancer · 2026Review
- Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Surgical Approach to Liver Metastasis from Gastroenteropancreatic Neuroendocrine Tumors in the Era of Precision Oncology.Cancers · 2026Review
- Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients.Journal of neuroendocrinology · 2026Article
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Pharmaceutics · 2026Article
- Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology.Diagnostics (Basel, Switzerland) · 2026Review
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Prognostic Role of Inflammatory Biomarkers in Gastrointestinal Neuroendocrine Neoplasms: A Cross-Sectional Study.Health science reports · 2025Article
- Review
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.Journal of neuroendocrinology · 2025Review
- Factors Influencing Costs of Cancer Care for Patients with Neuroendocrine Neoplasms.Neuroendocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide receptor radionuclide therapy (PRRT) using [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.